Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01507155 · ClinicalTrials.gov registry record · NA
An Open Label Study of Clinical Utility and Patient Outcomes of the Genecept Assay
A NA study, sponsored by Genomind.
- Completed
- Registry status
- NA
- Development phase
- 685
- Enrollment target
NCT01507155: Completed NA study, sponsored by Genomind.
NCT01507155 is a NA study that has completed, run by Genomind. The registered enrollment target is 685 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (51% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01507155, a NA study, has completed, sponsored by Genomind.
- COMPLETED
- Registry status
- NA
- Development phase
- 685 participants
- Enrollment target
Study Summary
Genomind has developed and introduced a battery of genetic tests, the Genecept Assay, which clinicians can administer to patients using a simple saliva sample technique. The present study proposes to enroll 1. Subjects (patients who have consented to using the Genecept Assay) and 2. Clinician study participants (clinicians who have ordered the Assay on behalf of their patients). This study will involve the collection of responses from both Subjects and clinician study participants with the intention of correlating this information to Subject genetic data.
Primary Outcome
To determine the efficacy of assay-guided treatment (AGT) in terms of illness severity, as measured by change from baseline using the clinician-administered CGI-I scale, which ranges from scores 1-7 (1=very much improved, 7=very much worse since initiation of treatment).
Interventions
- DEVICE Genecept Assay
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 685 participants |
| Start Date | 2013-04 |
| Est. Completion | 2014-05 |
| Phase | NA |
What the finished NCT01507155 record still lists
NCT01507155 is an interventional study that assigns participants to a tested intervention. The registered 685 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (51% lower).
The record links to 0 conditions, and to 1 intervention - of which Genecept Assay is the first listed.
NCT01507155 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01507155 about?
NCT01507155 is a clinical study titled "An Open Label Study of Clinical Utility and Patient Outcomes of the Genecept Assay". Genomind has developed and introduced a battery of genetic tests, the Genecept Assay, which clinicians can administer to patients using a simple saliva sample technique. The present study proposes to enroll 1. Subjects (patients who have consented to using the Genecept Assay) and 2. Clinician study ...
What is the current status of trial NCT01507155?
This trial is currently completed. It is a NA study. The enrollment target is 685 participants. The study started on 2013-04. Estimated completion is 2014-05.
What interventions are being tested in trial NCT01507155?
The interventions under investigation include: Genecept Assay (DEVICE).
Who is sponsoring clinical trial NCT01507155?
This trial is sponsored by Genomind, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01507155's enrollment target sits among peer trials
685 151st of 2000 higher than 1,850 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05099770 · 685 participants · Phase 3
Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease
- NCT05880199 · 685 participants
BSGM to Evaluate Patients With GI Symptoms
- NCT04333537 · 686 participants · Phase 2
Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer
- NCT06459180 · 686 participants · Phase 3
A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia